Phencyclidine (PCP) is a psychotomimetic drug that elicits schizo-phrenia-like symptoms in healthy persons, and administration of PCP to animals is used as a pharmacological model of schizo-phrenia. We recently demonstrated that systemic administration of PCP to rats produces long-lasting activation of medial prefrontal cortex (mPFC) neurons with augmentation of locomotor activity, whereas direct application of PCP to mPFC neurons has little effect on their firing activity. These findings suggest that PCP-induced activation of mPFC neurons is elicited mainly via excitatory inputs from regions outside the mPFC. In the present study, we examined effects of local application of PCP to the ventral hippocampus (vHIP) on firing activity of PFC ne...
Dysfunction of N-Methyl-d-aspartate receptors (NMDARs) is believed to underlie some of the symptoms ...
Phencyclidine (PCP), a non-competitive NMDA/glutamate receptor antagonist, is a psychotomimetic drug...
Phencyclidine (PCP) is an N-methyl-d-aspartate (NMDA) glutamate receptor channel noncompetitive anta...
AbstractSubchronic treatment with the N-methyl-d-aspartate (NMDA) antagonist phencyclidine (PCP) pro...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Subchronic administration of PCP, a psychotomimetic agent acting as an NMDAR channel blocker, produc...
Subchronic administration of PCP, a psychotomimetic agent acting as an NMDAR channel blocker, produc...
Rationale N-methyl-D-aspartate receptor (NMDA-R) hypofunction has been proposed to account for the p...
The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP) markedly disrupts thalamoc...
Non-competitive antagonists of the N-methyl-d-aspartate receptor (NMDA) such as phencyclidine (PCP) ...
Non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) and dizocilpine (MK-801) can ...
Phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, increases loc...
Non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) and dizocilpine (MK-801) can ...
Dysfunction of N-Methyl-d-aspartate receptors (NMDARs) is believed to underlie some of the symptoms ...
Phencyclidine (PCP), a non-competitive NMDA/glutamate receptor antagonist, is a psychotomimetic drug...
Phencyclidine (PCP) is an N-methyl-d-aspartate (NMDA) glutamate receptor channel noncompetitive anta...
AbstractSubchronic treatment with the N-methyl-d-aspartate (NMDA) antagonist phencyclidine (PCP) pro...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Subchronic administration of PCP, a psychotomimetic agent acting as an NMDAR channel blocker, produc...
Subchronic administration of PCP, a psychotomimetic agent acting as an NMDAR channel blocker, produc...
Rationale N-methyl-D-aspartate receptor (NMDA-R) hypofunction has been proposed to account for the p...
The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP) markedly disrupts thalamoc...
Non-competitive antagonists of the N-methyl-d-aspartate receptor (NMDA) such as phencyclidine (PCP) ...
Non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) and dizocilpine (MK-801) can ...
Phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, increases loc...
Non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) and dizocilpine (MK-801) can ...
Dysfunction of N-Methyl-d-aspartate receptors (NMDARs) is believed to underlie some of the symptoms ...
Phencyclidine (PCP), a non-competitive NMDA/glutamate receptor antagonist, is a psychotomimetic drug...
Phencyclidine (PCP) is an N-methyl-d-aspartate (NMDA) glutamate receptor channel noncompetitive anta...